MARKET

CANF

CANF

Can Fite Biophar
AMEX
2.440
+0.090
+3.83%
After Hours: 2.470 +0.03 +1.23% 17:37 12/01 EST
OPEN
2.310
PREV CLOSE
2.350
HIGH
2.460
LOW
2.310
VOLUME
42.14K
TURNOVER
0
52 WEEK HIGH
8.40
52 WEEK LOW
1.520
MARKET CAP
9.96M
P/E (TTM)
-6.9814
1D
5D
1M
3M
1Y
5Y
Recap: Can Fite Biofarma Q3 Earnings
Can fite biofarma will report its q3 earnings on november 30. The company's revenue is expected to be down $8 thousand from the same quarter last year. Can fitebiofarma missed estimates by 100.0%, missing by $0.0.
Benzinga · 3d ago
Can Fite Biophar: Report of foreign issuer
Press release · 3d ago
Can Fite Biofarma 9M Sales $588.00K Down From $613.00K YoY
Benzinga · 3d ago
Can-Fite Biopharma GAAP EPS of $0.00 beats by $0.43, revenue of $0.59M beats by $0.39M
Can-fite biopharma reports q3 gaap eps of $0.00, revenue of $ 0.59m beats by $.39m. The company's revenue for the quarter was down 3.3% from the same period last year. Can-fite had cash and cash equivalents of $7.94 million as of september 30, 2023.
Seeking Alpha · 3d ago
Weekly Report: what happened at CANF last week (1120-1124)?
Weekly Report · 6d ago
Can Fite Biophar: Report of foreign issuer
Press release · 11/22 22:01
Can Fite Biophar: Prospectus [Rule 424(b)(3)]
Press release · 11/22 22:01
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
NASDAQ · 11/22 12:23
More
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers Can Fite Biopharma Ltd stock information, including AMEX: CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.